I was just 39 years old, a mother of three young girls, facing a life expectancy of two to three years post-secondary breast cancer diagnosis. My chance to see my
Asha Umrawsingh
METUPUK are saddened by the news that one of our members and friend Asha Umrawsingh has died. Asha’s diagnosis and access to treatment was a roller coaster of how strict
METUPUK at the UK Interdisciplinary Breast Cancer Symposium
METUPUK (Metastatic Exchange To Unleash Power) attended the 2024 United Kingdom’s Interdisciplinary Breast Cancer Symposium in Birmingham, hosted by Breast Cancer Now and supported by numerous partners. It was a
PARP inhibitor Talazoparib recommended by NICE for the treatment of hereditary BRCA mutated metastatic breast cancer
METUPUK are delighted by the National Institute of Clinical Excellence (NICE) decision to recommend Talazoparib (Talzenna ®, Pfizer Ltd.) for treating HER2-negative, locally advanced or metastatic breast cancer with germline
NICE Methodology Roundtable Discussion
In November 2023 METUPUK trustee Madeleine Meynell was a panel member at the event Optimising NICE outcomes: Policy roundtable on the evolution of NICE methodology and how patient organisations can
Mindfulness and Metastatic Breast Cancer at Christmas
Living with an incurable form of cancer presents lots of physical, emotional and mental challenges not least of which are the expectations and pressures associated with annual celebrations and milestones;
NICE invites comments from the public on the draft guidance to not recommend the parp inhibitor talazoparib
METUPUK are disappointed by the National Institute of Clinical Excellence (NICE) decision to not recommend talazoparib (Talzenna ®, Pfizer Ltd.) for treating HER2-negative, locally advanced or metastatic breast cancer with
“Fighting” Metastatic Breast Cancer Platitudes
Seagen Biotech company asked two metastatic breast cancer (MBC) advocates Eva Schumacher from Mamma Mia online German cancer magazine and patient living with MBC and myself Jo Taylor founder of
The Irony of Metastatic Breast Cancer – Mary Huckle
Many of our followers on social media will remember Mary Huckle and her tireless campaigning for #metastaticbreastcancer awareness. This blog post is the last content she wrote for us, a
METUPUK are delighted by the Scottish Medicines Consortium (SMC) acceptance of Enhertu (trastuzumab deruxtecan) for routine use on the NHS.
METUPUK are delighted by the Scottish Medicines Consortium (SMC) acceptance of Enhertu (trastuzumab deruxtecan) for routine use on the NHS. The Scottish Medicines Consortium (SMC) has accepted: Trastuzumab deruxtecan (Enhertu)